ReviewJournal of cardiothoracic surgery2026
Robotic thymectomy in myasthenia gravis: current evidence, outcomes, and future perspective.
Review in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Robotic-assisted thymectomy has become a well-established treatment option for acetylcholine receptor-positive myasthenia gravis. This review provides a synthesis of current evidence regarding its technical evolution, surgical outcomes, neurological efficacy, and future directions. Robotic thymectomy, particularly using platforms such as the da Vinci system, offers high-definition three-dimensional visualization, tremor filtration, and articulating instruments that enable precise dissection within the confined space of the mediastinum. Several surgical approaches are available, including unilateral right or left transthoracic, subxiphoid, and emerging single-port techniques—each with distinct advantages. The procedure is associated with excellent safety and feasibility, characterized by low conversion rates, minimal blood loss, short hospital stays, and a low incidence of major complications. Neurological outcomes are promising, with clinical improvement observed in 75–85% of patients at five years and complete stable remission rates ranging from 18% to 40%. A consistent steroid-sparing effect has also been reported. Key prognostic factors for favorable outcomes include younger age, milder disease severity, and non-thymomatous pathology. Comparative studies indicate that robotic thymectomy offers superior perioperative outcomes relative to open sternotomy, while demonstrating comparable efficacy to video-assisted thoracoscopic surgery, with potential qualitative advantages. The procedure is increasingly being applied in special populations, including juvenile, elderly, and ocular myasthenia gravis patients. Future directions include prospective trials, biomarker research, and technological innovations such as single-port robotic platforms. In conclusion, this narrative review is based on a structured literature search of PubMed and Web of Science. While the current evidence largely derives from retrospective cohort studies and case series, the aggregated data consistently demonstrate that robotic thymectomy represents a safe and effective surgical option that effectively balances the goals of radical resection and minimal morbidity. This review uniquely integrates surgical outcomes, neurological efficacy, and patient selection criteria into a single synthesis, providing a clinically actionable framework for multidisciplinary decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.